Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | FAAH | O00519 | 5/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20581538 | 1.00 | DGKA (0.42) | DGKAALDH1A1LMNAFAAHCNR1 | |
| SCHEMBL9730121 | 0.93 | ALDH1A1 (0.43) | DGKAALDH1A1LMNAFAAHCNR1 | |
| SCHEMBL22141529 | 0.91 | ALDH1A1 (0.38) | DGKAALDH1A1LMNAFAAHCNR1 | |
| SCHEMBL22127530 | 0.87 | FAAH (0.40) | DGKAALDH1A1LMNAFAAHCNR1 | |
| SCHEMBL29308246 | 0.87 | DGKA (0.61) | DGKAALDH1A1LMNAFAAHCNR1 | |
| SCHEMBL23117589 | 0.87 | DGKA (0.39) | DGKAALDH1A1LMNAFAAHCNR1 | |
| SCHEMBL22127583 | 0.87 | DGKA (0.39) | DGKAALDH1A1LMNAFAAHCNR1 | |
| SCHEMBL22127529 | 0.87 | FAAH (0.40) | DGKAALDH1A1LMNAFAAHCNR1 | |
| SCHEMBL21266960 | 0.87 | DGKA (0.61) | DGKAALDH1A1LMNAFAAHCNR1 | |
| SCHEMBL29582411 | 0.87 | DGKA (0.61) | DGKAALDH1A1LMNAFAAHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634430-B1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3801496-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3801587-A1 | ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210085640-A1 | ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-03-25 | — | — | US | disclosed |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING, INC. | 2020-06-25 | — | — | US | disclosed |
| US-8287849-B2 | Biodegradable poly(beta-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-10-16 | — | — | US | disclosed |
| US-RE43612-E1 | Biodegradable poly(β-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120065358-A1 | BIODEGRADABLE POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-03-15 | — | — | US | disclosed |
| US-7943179-B2 | Drug delivery particle; useful in genetic vaccination; eg poly(beta-amino esters) | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20110059172-A1 | THERAPEUTIC COMPOSITIONS | TZIANABOS ARTHUR | 2011-03-10 | — | — | US | disclosed |
| US-20100036084-A1 | BIODEGRADABLE POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-02-11 | — | — | US | disclosed |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-02 | — | — | US | disclosed |
| US-7427394-B2 | Delivering labile agents; buffering effect; transfecting nucleic acids; nontoxic | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080145338-A1 | Acrylate-terminated poly(beta-amino esters); high throughput assay; biocompatability | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145338-A1 | Acrylate-terminated poly(beta-amino esters); high throughput assay; biocompatability | ACP1, ILK, BCAT2 | DGKA 2497/4885ALDH1A1 891/4885LMNA 1926/4885 |
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | PARN, PARG, POLL | DGKA 1844/4885ALDH1A1 2664/4885LMNA 566/4885 |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | DGKA 652/4885ALDH1A1 410/4885LMNA 1035/4885 |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | PARN, PARG, POLL | DGKA 1844/4885ALDH1A1 2664/4885LMNA 566/4885 |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | DGKA 652/4885ALDH1A1 410/4885LMNA 1035/4885 |
| US-20210085640-A1 | ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER | ACAT2, ACAT1, FABP6 | DGKA 392/4885ALDH1A1 290/4885LMNA 2944/4885 |
| US-20110059172-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, ACP1, TUBB3 | DGKA 3633/4885ALDH1A1 1769/4885LMNA 687/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | DGKA 560/4885ALDH1A1 1112/4885LMNA 1830/4885 |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | DGKA 652/4885ALDH1A1 410/4885LMNA 1035/4885 |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | DGKA 652/4885ALDH1A1 410/4885LMNA 1035/4885 |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | DGKA 652/4885ALDH1A1 410/4885LMNA 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.